Antibe Therapeutics Overview

  • Founded
  • 2004
Founded
  • Status
  • Public
  • Employees
  • 44
Employees
  • Stock Symbol
  • ATE
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $3.12
  • (As of Monday Closing)

Antibe Therapeutics General Information

Description

Antibe Therapeutics Inc develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Its operating segment includes Antibe and Citagenix. The company generates maximum revenue from Citagenix segment and geographically from Canada. Citagenix segment is a marketer and distributor of regenerative medicines serving the dental and orthopaedic market places.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
TSE
Primary Office
  • 15 Prince Arthur Avenue
  • Toronto, Ontario M5R 1B2
  • Canada
+1 (416) 000-0000

Antibe Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antibe Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.12 $3.16 $2.29 - $5.92 $160M 51.4M 107K -$0.59

Antibe Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019 FY 2018 31-Mar-2018
EV 102,723 117,770 50,623 57,241
Revenue 6,952 7,506 7,267 6,630
EBITDA (18,547) (13,682) (9,040) (4,804)
Net Income (20,286) (14,537) (9,764) (5,788)
Total Assets 19,227 9,757 11,099 9,672
Total Debt 210 1,691 1,552 1,190
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Antibe Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Antibe Therapeutics‘s full profile, request access.

Request a free trial

Antibe Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Antibe Therapeutics Inc develops safer, non-addictive medicines for pain and inflammation. Its technology involves linki
Drug Discovery
Toronto, Canada
44 As of 2019
000.00
00000000 000.00

0000000

s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000000 00000

0.0. 000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000000000000
Sunrise, FL
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antibe Therapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ViaCyte Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
0.0. 0000 0000 Formerly VC-backed Sunrise, FL 00 000.00 000000000 000.00
00000000 Venture Capital-Backed South San Francisco, CA 00 00000 000000000 00000
000000000 Corporation Melbourne, Australia 000 00000 000000000 00000
To view Antibe Therapeutics’s complete competitors history, request access »

Antibe Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Daniel Legault JD Chief Executive Officer & Board Member
John Wallace Ph.D Chief Scientific Officer & Board Member
David Vaughan Ph.D Executive
Rami Batal Ph.D Senior Vice President
Joseph Stauffer MD Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Antibe Therapeutics Board Members (5)

Name Representing Role Since
Daniel Legault JD Antibe Therapeutics Chief Executive Officer & Board Member 000 0000
John Wallace Ph.D Antibe Therapeutics Chief Scientific Officer & Board Member 000 0000
Roderick Flower Ph.D Antibe Therapeutics Board Member 000 0000
Walt Macnee Antibe Therapeutics Chairman & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Antibe Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antibe Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Antibe Therapeutics‘s full profile, request access.

Request a free trial

Antibe Therapeutics Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 02-Feb-2016 000000000 00000 Surgical Devices 000000 0000000 00
Citagenix 16-Oct-2015 Merger/Acquisition 00.000 Surgical Devices 000000 0000000 00
To view Antibe Therapeutics’s complete investments and acquisitions history, request access »

Antibe Therapeutics Subsidiaries (1)

Company Name Industry Location Founded
000000000 Surgical Devices Laval, Canada 0000
To view Antibe Therapeutics’s complete subsidiaries history, request access »